Investing in new technology: the PET experience

Bradbury, Ian; Facey, Karen; Laking, George; Sharp, P.

doi:10.1038/sj.bjc.6601109

Cited by 7 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been demonstrated that PET is effective for the initial diagnosis of both non-small-cell lung cancer (NSCLC) and Hodgkin's disease and/or the assessment of disease extent (7;8). In these applications, several cost-effectiveness studies (1–3;4;9;11;13–17;19–24) have suggested that PET could save time and money by better guiding diagnostic procedures and reducing unnecessary and inappropriate treatments.…”

mentioning

confidence: 99%

Assessing short-term effects and costs at an early stage of innovation: The use of positron emission tomography on radiotherapy treatment decision making

Remonnay

Morelle

Pommier

et al. 2008

Int J Technol Assess Health Care

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Assessing short-term effects and costs at an early stage of innovation: The use of positron emission tomography on radiotherapy treatment decision making

Remonnay

Morelle

Pommier

et al. 2008

Int J Technol Assess Health Care

View full text Add to dashboard Cite

show abstract

“…Published studies on clinical effectiveness and cost-effectiveness analysis (comparing accuracy of PET and other diagnostic imaging techniques) have contributed to a growing body of information and evidence [18,[25][26][27]. However, the results from this literature are mixed.…”

Section: Positron Emission Tomographymentioning

confidence: 99%

“…At present, nearly 90% of PET applications are in oncology [18,19]. This technology can detect cancerous lesions due to their high rate of glucose utilization.…”

Section: Positron Emission Tomographymentioning

confidence: 99%

The timing of adoption of positron emission tomography: a real options approach

Pertile

Torri

Flor

et al. 2008

Health Care Manag Sci

View full text Add to dashboard Cite

This paper presents the economic evaluation from a hospital's perspective of the investment in positron emission tomography, adopting a real options approach. The installation of this equipment requires a major capital outlay, while uncertainty on several key variables is substantial. The value of several timing strategies, including sequential investment, is determined taking into account that future decisions will be based on the information available at that time. The results show that adopting this approach may have an impact on the timing of investment, because postponing the investment may be optimal even when the Expected Net Present Value of the project is positive.

show abstract

“…Auch gibt es auch Überlegungen, ob randomisierte kontrollierte Studien der beste und einzige Weg sind, um das Outcome der PET zu belegen (18), oder ob nicht auch z.B. ein Modelling anhand von vielfach bereits vorhandenen Daten zur Genauigkeit der PET im Vergleich zu anderen Untersuchungen die gewünschten Informationen liefern kann (3,5 Abb.1 PET in der Onkologie: Vergütete Indikationen in Europa (modifiziert nach (7)). …”

Section: Fast 400 000 Menschen Erkranken Jährlich In Deutschland Anunclassified

Positronen-Emissions-Tomografie in der Onkologie - Bestandteil der ärztlichen Behandlungskunst

Bamberg

Diehl²,

Herrmann³

et al. 2006

Dtsch med Wochenschr

View full text Add to dashboard Cite

Early inclusion of positron emission tomography (PET) in the stepwise oncological diagnosis improves tumor staging and can make further costly diagnostic and inadequate therapeutic measures superfluous. The advantage of this method, in answering the many questions that arise, has been supported by an extensive literature and analysis of interdisciplinary data. Its use is therefore demanded by doctors working in oncology. Surgeons and radiotherapists demand PET studies before local treatment is started so that patients with advanced-stage cancer are spared invasive local therapeutic measures. Oncologists take advantage of PET"s potential to administer stage-related chemotherapy and provide evidence of its efficacy. Expensive treatment regimens can be immediately tested for their efficacy and, if ineffective, can be replaced by a more suitable combination of chemotherapeutic agents. For this purpose combined PET and CT can be considered the (future) standard for oncological diagnosis. Manufacturers have already positioned themselves to provide PET only as part of combined PET/CT equipment. If these advances are not used, patients are deprived of optimal treatment. Furthermore, PET provides considerable potential for cost savings by avoiding expensive measures that do not prolong life. Responsible use of these resources within the health service system requires the early use of PET in the staging of diagnostic methods so that therapeutic options can be weighed through interdisciplinary consultation. The patient can thus be given optimal information and included in therapeutic decisions. It is our obligation as doctors to demand from the decision makers that PET equipment be provided for use in accordance with correct indications and to reimburse the costs as is already the case in other parts of Europe.

show abstract

Investing in new technology: the PET experience

Cited by 7 publications

References 20 publications

Assessing short-term effects and costs at an early stage of innovation: The use of positron emission tomography on radiotherapy treatment decision making

Assessing short-term effects and costs at an early stage of innovation: The use of positron emission tomography on radiotherapy treatment decision making

The timing of adoption of positron emission tomography: a real options approach

Positronen-Emissions-Tomografie in der Onkologie - Bestandteil der ärztlichen Behandlungskunst

Contact Info

Product

Resources

About